Cellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC
March 21, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 21, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the United...
Cellectar Biosciences Reports 2016 Company Performance and Continued Progress in First Quarter 2017
March 15, 2017 16:15 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 15, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces financial...
Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences’ Intellectual Property Portfolio
March 14, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 14, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the Japanese...
Cellectar Biosciences to Host Conference Call on March 15 to Report Fourth Quarter and Year-End 2016 Financial Results and Corporate Performance
March 09, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 09, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces that...
Expanding Its Strategic Relationship with Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement
March 08, 2017 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 08, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces it has entered...
Cellectar Biosciences to Present at 29th Annual Roth Conference
March 06, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., March 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announces today that its president and CEO,...
Cellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches 17.7 Months
February 27, 2017 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today provides an update of its Phase I clinical...
Upon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma
February 22, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces the successful completion of...
UPDATE -- Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference
February 13, 2017 07:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO, Jim...
Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference
February 07, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO,...